Home | Welcome to Contract Pharma   
Last Updated Tuesday, October 21 2014
Print RSS Feed

Financial Results: Patheon 4Q12



Published December 17, 2012
Related Searches: Development Services CMO Development Manufacturing
Patheon

4Q Revenues: $210.0 million (flat) 

4Q Loss: $23.1 million (loss of $9.9 million in 4Q11)

YTD Revenues: $749.1 million (+7%)

YTD Loss: $106.7 million (loss of $16.4 million YTD11)

Comments: Commercial manufacturing revenues in the quarter were $172.7 million, up 18%, and for the year were $610.7 million, up 7%. Pharmaceutical Development Services revenues in the quarter were $37.5 million, up 7%, and for the year were $138.4 million, up 9%. The loss before discontinued operations was $106.4 million YTD compared to a loss of $15.8 million last year, primarily due to the asset impairment charge of $57.9 million related to closing the Swindon, UK facility.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On